Microhomology-mediated end joining drives complex rearrangements and over-expression of MYC and PVT1 in multiple myeloma
Authors:
- Aneta MikulasovaAMAneta Mikulasova
- Cody AshbyCACody Ashby
- Ruslana G. TytarenkoRTRuslana G. Tytarenko
- Pingping QuPQPingping Qu
- Adam RosenthalARAdam Rosenthal
- Judith A. DentJDJudith A. Dent
- Katie R. RyanKRKatie R. Ryan
- Michael A. BauerMichael A. Bauer
- Christopher P. WardellCWChristopher P. Wardell
- Antje HoeringAHAntje Hoering
- Konstantinos MavrommatisKMKonstantinos Mavrommatis
- Matthew TrotterMTMatthew Trotter
Preprint
Abstract
MYC is a widely acting transcription factor and its deregulation is a crucial event in many human cancers. MYC is important biologically and clinically in multiple myeloma, but the mechanisms underlying its dysregulation are poorly understood. We show that MYC rearrangements are present in 36.0% of newly diagnosed myeloma patients, as detected in the largest set of next generation sequencing data to date (n=1267). Rearrangements were complex and associated with increased expression of MYC and PVT1 , but not other genes at 8q24. The highest effect on gene expression was detected in cases where the MYC locus is juxtaposed next to super-enhancers associated with genes such as IGH , IGK , IGL , TXNDC5 / BMP6 , FAM46C and FOXO3 . We identified three hotspots of recombination at 8q24, one of which is enriched for IGH-MYC translocations. Breakpoint analysis indicates primary myeloma rearrangements involving the IGH locus occur through non-homologous end joining, whereas secondary MYC rearrangements occur through microhomology-mediated end joining. This mechanism is different to lymphomas, where non-homologous end joining generates MYC rearrangements. Rearrangements resulted in over-expression of key genes and ChIP-seq identified that HK2 , a member of the glucose metabolism pathway, is directly over-expressed through binding of MYC at its promoter.Keywords
All Related Versions
- Published version: Haematologica, 105 (4), 1055.
This publication has 59 references indexed in Scilit:
- Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patientsBlood Cancer Journal, 2014
- Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myelomaLeukemia, 2014
- The genetic architecture of multiple myelomaNature Reviews Cancer, 2012
- Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myelomaLeukemia, 2011
- Mechanism and Regulation of Class Switch RecombinationAnnual Review of Immunology, 2008
- Ras and Myc can drive oncogenic cell proliferation through individual D-cyclinsOncogene, 2005
- AID Is Required for c-myc/IgH Chromosome Translocations In VivoCell, 2004
- c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progressionGenes & Development, 2002
- Genetic dissection of c-myc apoptotic pathwaysOncogene, 2000
- Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myelomaProceedings of the National Academy of Sciences, 1996